Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fennec Pharmaceuticals Inc (NQ: FENC ) 5.530 +0.090 (+1.65%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Fennec Pharmaceuticals Inc < Previous 1 2 3 Next > FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 August 13, 2024 FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace 3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! July 29, 2024 These dirt cheap stocks under $10 have the potential to rise rapidly and create fortunes for bold investors. Via InvestorPlace Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 14, 2024 Via Benzinga Fennec Pharmaceuticals's Earnings Outlook March 20, 2024 Via Benzinga Earnings Scheduled For November 6, 2023 November 06, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. Via Benzinga Preview: Fennec Pharmaceuticals's Earnings November 03, 2023 Via Benzinga Analyst Ratings for Fennec Pharmaceuticals June 21, 2023 Via Benzinga FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 14, 2024 FENC stock results show that Fennec Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 March 21, 2024 FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. Via InvestorPlace Earnings Scheduled For March 21, 2024 March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Via Benzinga Recap: Fennec Pharmaceuticals Q1 Earnings May 11, 2023 Via Benzinga Earnings Outlook For Fennec Pharmaceuticals May 10, 2023 Via Benzinga Analyst Ratings for Fennec Pharmaceuticals April 06, 2023 Via Benzinga Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Highlighted for Surprising Price Action March 18, 2024 Via Investor Brand Network Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Making Surprising Moves in Monday Session November 06, 2023 Via Investor Brand Network 7 Biotech Stocks Sitting in the Sweet Spot March 24, 2023 Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. Via InvestorPlace US Stocks Open Lower; Dow Dips 250 Points January 25, 2023 U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.74% to 33,484.47 while the NASDAQ fell... Via Benzinga Expert Ratings for Fennec Pharmaceuticals November 22, 2022 Via Benzinga What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals November 22, 2022 Via Benzinga 4 Analysts Have This to Say About Fennec Pharmaceuticals November 22, 2022 Via Benzinga Where Fennec Pharmaceuticals Stands With Analysts November 22, 2022 Via Benzinga After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss September 21, 2022 Via Benzinga Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday September 22, 2022 Gainers Via Benzinga Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session September 21, 2022 Gainers Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022 September 07, 2022 Upgrades Via Benzinga Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know August 31, 2022 After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. Via Benzinga NASDAQ:FENC Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Fennec Pharmaceuticals Inc. June 01, 2022 San Diego, CA -- (SBWIRE) -- 06/01/2022 -- Certain directors of Fennec Pharmaceuticals Inc. are under investigation over potential breaches of fiduciary duties. Via SBWire U.S. FDA accepts Fennec Pharma's New Drug Application (NDA) Resubmission for PEDMARK April 27, 2022 Fennec Pharmaceuticals Inc. (NASDAQ: FENC) announced that the U.S. Via Benzinga NASDAQ:FENC Shareholder Notice: Deadline on April 11, 2022 in Lawsuit Against Fennec Pharmaceuticals Inc. April 11, 2022 San Diego, CA -- (SBWIRE) -- 04/11/2022 -- A deadline is coming up on April 11, 2022 in the lawsuit filed for certain investors of Fennec Pharmaceuticals Inc. (NASDAQ:FENC). Via SBWire FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm April 11, 2022 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.